Top

Published in:

Open Access 01-12-2024 | Headache | Review

The World Health Organization Intersectoral Global Action Plan on Epilepsy and Other Neurological Disorders and the headache revolution: from headache burden to a global action plan for headache disorders

Authors: Matilde Leonardi, Paolo Martelletti, Rami Burstein, Arianna Fornari, Licia Grazzi, Alla Guekht, Richard B. Lipton, Dimos Dimitrios Mitsikostas, Jes Olesen, Mayowa Ojo Owolabi, Elena Ruiz De la Torre, Simona Sacco, Timothy J. Steiner, Nirmal Surya, Takao Takeshima, Cristina Tassorelli, Shuu-Jiun Wang, Tissa Wijeratne, Shengyuan Yu, Alberto Raggi

Published in: The Journal of Headache and Pain | Issue 1/2024

Abstract

The World Health Organization (WHO) Intersectoral Global Action Plan on Epilepsy and Other Neurological Disorders was developed by WHO to address the worldwide challenges and gaps in provision of care and services for people with epilepsy and other neurological disorders and to ensure a comprehensive, coordinated response across sectors to the burden of neurologic diseases and to promote brain health across life-course. Headache disorders constitute the second most burdensome of all neurological diseases after stroke, but the first if young and midlife adults are taken into account. Despite the availability of a range of treatments, disability associated with headache disorders, and with migraine, remains very high. In addition, there are inequalities between high-income and low and middle income countries in access to medical care. In line with several brain health initiatives following the WHOiGAP resolution, herein we tailor the main pillars of the action plan to headache disorders: (1) raising policy prioritization and strengthen governance; (2) providing effective, timely and responsive diagnosis, treatment and care; (3) implementing strategies for promotion and prevention; (4) fostering research and innovation and strengthen information systems. Specific targets for future policy actions are proposed. The Global Action Plan triggered a revolution in neurology, not only by increasing public awareness of brain disorders and brain health but also by boosting the number of neurologists in training, raising research funding and making neurology a public health priority for policy makers. Reducing the burden of headache disorders will not only improve the quality of life and wellbeing of people with headache but also reduce the burden of neurological disorders increasing global brain health and, thus, global population health.

World Health Organization (2023) Intersectoral global action plan on Epilepsy and other neurological disorders 2022–2031. World Health Organization, Geneva

Steiner TJ, Birbeck GL, Jensen RH et al (2022) The global campaign turns 18: a brief review of its activities and achievements. J Headache Pain 23:49. https://doi.org/10.1186/s10194-022-01420-0CrossRefPubMedPubMedCentral

Steiner TJ, World Headache Alliance (2004) Lifting the burden: the global campaign against headache. Lancet Neurol 3:204–205. https://doi.org/10.1016/S1474-4422(04)00703-3CrossRefPubMed

Leonardi M, Raggi A (2019) A narrative review on the burden of migraine: when the burden is the impact on people’s life. J Headache Pain 20:41. https://doi.org/10.1186/s10194-019-0993-0CrossRefPubMedPubMedCentral

GBD 2019 Diseases and Injuries Collaborators (2020) Global burden of 369 Diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the global burden of Disease Study 2019. Lancet 396:1204–1222CrossRef

Safiri S, Pourfathi H, Eagan A et al (2022) Global, regional, and national burden of migraine in 204 countries and territories, 1990 to 2019. Pain 163:e293–e309. https://doi.org/10.1097/j.pain.0000000000002275CrossRefPubMed

Ashina M, Buse DC, Ashina H et al (2021) Migraine: integrated approaches to clinical management and emerging treatments. Lancet 397:1505–1518. https://doi.org/10.1016/S0140-6736(20)32342-4CrossRefPubMed

Robbins MS (2021) Diagnosis and management of Headache: a review. JAMA 325:1874–1885. https://doi.org/10.1001/jama.2021.1640CrossRefPubMed

Ferrari MD, Goadsby PJ, Burstein R et al (2022) Migraine. Nat Rev Dis Primers 8:2. https://doi.org/10.1038/s41572-021-00328-4CrossRefPubMed

10.

Tepper SJ (2019) Acute Treatment of Migraine. Neurol Clin 37:727–742. https://doi.org/10.1016/j.ncl.2019.07.006CrossRefPubMed

11.

Ailani J (2021) Acute Migraine Treatment. Continuum (Minneap Minn) 27:597–612. https://doi.org/10.1212/CON.0000000000000956CrossRefPubMed

12.

Burch R (2021) Preventive migraine treatment. Continuum (Minneap Minn) 27:613–632. https://doi.org/10.1212/CON.0000000000000957CrossRefPubMed

13.

Grazzi L, Toppo C, D’Amico D et al (2021) Non-pharmacological approaches to Headaches: non-invasive neuromodulation, Nutraceuticals, and behavioral approaches. Int J Environ Res Public Health 18:1503. https://doi.org/10.3390/ijerph18041503CrossRefPubMedPubMedCentral

14.

Steiner TJ, Jensen R, Katsarava Z et al (2021) Structured headache services as the solution to the ill-health burden of headache: 1. Rationale and description. J Headache Pain 22:78. https://doi.org/10.1186/s10194-021-01265-zCrossRefPubMedPubMedCentral

15.

Tinelli M, Leonardi M, Paemeleire K et al (2021) Structured headache services as the solution to the ill-health burden of headache. 2. Modelling effectiveness and cost-effectiveness of implementation in Europe: methodology. J Headache Pain 22:99. https://doi.org/10.1186/s10194-021-01310-xCrossRefPubMedPubMedCentral

16.

Tinelli M, Leonardi M, Paemeleire K et al (2021) Structured headache services as the solution to the ill-health burden of headache. 3. Modelling effectiveness and cost-effectiveness of implementation in Europe: findings and conclusions. J Headache Pain 22:90. https://doi.org/10.1186/s10194-021-01305-8CrossRefPubMedPubMedCentral

17.

Martelletti P, Leonardi M, Ashina M et al (2023) Rethinking headache as a global public health case model for reaching the SDG 3 HEALTH by 2030. J Headache Pain 24:140. https://doi.org/10.1186/s10194-023-01666-2CrossRefPubMedPubMedCentral

18.

Owolabi MO, Leonardi M, Bassetti C et al (2023) Global synergistic actions to improve brain health for human development. Nat Rev Neurol 19:371–383. https://doi.org/10.1038/s41582-023-00808-zCrossRefPubMedPubMedCentral

19.

World Health Organization (2001) International Classification of Functioning, disability and health. World Health Organization, Geneva

20.

Caponnetto V, Deodato M, Robotti M et al (2021) Comorbidities of primary headache disorders: a literature review with meta-analysis. J Headache Pain 22:71. https://doi.org/10.1186/s10194-021-01281-zCrossRefPubMedPubMedCentral

21.

Wijeratne T, Grisold W, Dodick D, Carroll W (2019) World Brain Day 2019: migraine, the painful truth. Lancet Neurol 18(10):914. https://doi.org/10.1016/S1474-4422(19)30281-9CrossRefPubMed

22.

Wijeratne T, Dodick DW, Lewis SL, Guekht A, Pochigaeva K, Grisold W (2023) World Brain Day 2023 - Brain Health and disability: leave no one behind. J Neurol Sci 451:120720. https://doi.org/10.1016/j.jns.2023.120720CrossRefPubMed

23.

Linde M, Gustavsson A, Stovner LJ et al (2012) The cost of headache disorders in Europe: the Eurolight project. Eur J Neurol 19:703–711. https://doi.org/10.1111/j.1468-1331.2011.03612.xCrossRefPubMed

24.

Raggi A, Grazzi L, Guastafierro E et al (2022) Addressing the cost of chronic and episodic migraine and its main drivers: a short-term longitudinal analysis from a third-level Italian center. Neurol Sci 43:5717–5724. https://doi.org/10.1007/s10072-022-06164-yCrossRefPubMed

25.

Tobin J, Ford JH, Tockhorn-Heidenreich A et al (2022) Annual indirect cost savings in patients with episodic or chronic migraine: post-hoc analyses from multiple galcanezumab clinical trials. J Med Econ 25:630–639. https://doi.org/10.1080/13696998.2022.2071528CrossRefPubMed

26.

Bulsei J, Leplus A, Donnet A et al (2021) Occipital nerve stimulation for refractory chronic cluster headache: a cost-effectiveness study. Neuromodulation 24:1083–1092. https://doi.org/10.1111/ner.13394CrossRefPubMed

27.

Amoozegar F, Khan Z, Oviedo-Ovando M, Sauriol S, Rochdi D (2022) The Burden of Illness of Migraine in Canada: New insights on Humanistic and Economic cost. Can J Neurol Sci 49:249–262. https://doi.org/10.1017/cjn.2021.75CrossRefPubMed

28.

Mahon R, Lang A, Vo P et al (2021) Cost-effectiveness of Erenumab for the Preventive Treatment of Migraine in patients with prior treatment failures in Sweden. Pharmacoeconomics 39:357–372. https://doi.org/10.1007/s40273-020-00996-2CrossRefPubMed

29.

Hansson-Hedblom A, Axelsson I, Jacobson L, Tedroff J, Borgström F (2020) Economic consequences of migraine in Sweden and implications for the cost-effectiveness of onabotulinumtoxinA (Botox) for chronic migraine in Sweden and Norway. J Headache Pain 21:99. https://doi.org/10.1186/s10194-020-01162-xCrossRefPubMedPubMedCentral

30.

Irimia P, Santos-Lasaosa S, García Bujalance L, Ramos Pinazo L, Rubio-Rodríguez D, Rubio-Terrés C (2021) Cost of fremanezumab, erenumab, galcanezumab and onabotulinumtoxinA associated adverse events, for migraine prophylaxis in Spain. Expert Rev Pharmacoecon Outcomes Res 21:285–297. https://doi.org/10.1080/14737167.2020.1768850CrossRefPubMed

31.

Schoenbrunner AR, Khansa I, Janis JE (2020) Cost-effectiveness of Long-Term, targeted OnabotulinumtoxinA versus peripheral trigger site deactivation Surgery for the treatment of refractory migraine headaches. Plast Reconstr Surg 145:401e–406e. https://doi.org/10.1097/PRS.0000000000006480CrossRefPubMed

32.

Giannouchos TV, Mitsikostas DD, Ohsfeldt RL, Vozikis A, Koufopoulou P (2019) Cost-effectiveness analysis of Erenumab Versus OnabotulinumtoxinA for patients with chronic migraine Attacks in Greece. Clin Drug Investig 39(10):979–990. https://doi.org/10.1007/s40261-019-00827-zCrossRefPubMed

33.

Mortel D, Kawatu N, Steiner TJ, Saylor D (2022) Barriers to headache care in low- and middle-income countries. eNeurologicalSci 29:100427. https://doi.org/10.1016/j.ensci.2022.100427CrossRefPubMedPubMedCentral

34.

Lipton RB, Serrano D, Holland S, Fanning KM, Reed ML, Buse DC (2013) Barriers to the diagnosis and treatment of migraine: effects of sex, income, and headache features. Headache 53(1):81–92. https://doi.org/10.1111/j.1526-4610.2012.02265.xCrossRefPubMed

35.

Viana M, Tassorelli C, Allena M, Nappi G, Sjaastad O, Antonaci F (2013) Diagnostic and therapeutic errors in trigeminal autonomic cephalalgias and hemicrania continua: a systematic review. J Headache Pain 14:14. https://doi.org/10.1186/1129-2377-14-14CrossRefPubMedPubMedCentral

36.

Cortijo E, Guerrero AL, Herrero S et al (2012) Hemicrania continua in a headache clinic: referral source and diagnostic delay in a series of 22 patients. J Headache Pain 13:567–569. https://doi.org/10.1007/s10194-012-0471-4CrossRefPubMedPubMedCentral

37.

Frederiksen HH, Lund NL, Barloese MC, Petersen AS, Jensen RH (2020) Diagnostic delay of cluster headache: a cohort study from the Danish cluster Headache Survey. Cephalalgia 40:49–56. https://doi.org/10.1177/0333102419863030CrossRefPubMed

38.

Kim BS, Chung PW, Kim BK et al (2022) Diagnostic Delay and its predictors in Cluster Headache. Front Neurol 13:827734. https://doi.org/10.3389/fneur.2022.827734CrossRefPubMedPubMedCentral

39.

Diamond ML (2002) The role of concomitant headache types and non-headache co-morbidities in the underdiagnosis of migraine. Neurology 58:S3-9. https://doi.org/10.1212/wnl.58.9_suppl_6.s3CrossRefPubMed

40.

Cevoli S, D’Amico D, Martelletti P et al (2009) Underdiagnosis and undertreatment of migraine in Italy: a survey of patients attending for the first time 10 headache centres. Cephalalgia 29:1285–1293. https://doi.org/10.1111/j.1468-2982.2009.01874.xCrossRefPubMed

41.

Viana M, Khaliq F, Zecca C et al (2020) Poor patient awareness and frequent misdiagnosis of migraine: findings from a large transcontinental cohort. Eur J Neurol 27:536–541. https://doi.org/10.1111/ene.14098CrossRefPubMed

42.

Arroyo-Quiroz C, Kurth T, Cantu-Brito C, Lopez-Ridaura R, Romieu I, Lajous M (2014) Lifetime prevalence and underdiagnosis of migraine in a population sample of Mexican women. Cephalalgia 34:1088–1092. https://doi.org/10.1177/0333102414529196CrossRefPubMed

43.

Adams AM, Buse DC, Leroux E (2023) Chronic Migraine Epidemiology and Outcomes - International (CaMEO-I) study: methods and multi-country baseline findings for diagnosis rates and care. Cephalalgia 43(6):3331024231180611. https://doi.org/10.1177/03331024231180611CrossRefPubMed

44.

O’Brien HL, Cohen JM (2015) Young adults with headaches: the transition from adolescents to adults. Headache 55:1404–1409. https://doi.org/10.1111/head.12706CrossRefPubMed

45.

Antonaci F, Voiticovschi-Iosob C, Di Stefano AL, Galli F, Ozge A, Balottin U (2014) The evolution of headache from childhood to adulthood: a review of the literature. J Headache Pain 15:15. https://doi.org/10.1186/1129-2377-15-15CrossRefPubMedPubMedCentral

46.

VanderPluym JH, Charleston L 4th, Stitzer ME, Flippen CC 2, Armand CE, Kiarashi J (2022) A review of Underserved and vulnerable populations in Headache Medicine in the United States: challenges and opportunities. Curr Pain Headache Rep 26:415–422. https://doi.org/10.1007/s11916-022-01042-wCrossRefPubMed

47.

Bigal ME, Arruda MA (2010) Migraine in the pediatric population–evolving concepts. Headache 50:1130–1143. https://doi.org/10.1111/j.1526-4610.2010.01717.xCrossRefPubMed

48.

Negro A, Delaruelle Z, Ivanova TA et al (2017) Headache and pregnancy: a systematic review. J Headache Pain 18:106. https://doi.org/10.1186/s10194-017-0816-0CrossRefPubMedPubMedCentral

49.

Burch R (2019) Headache in pregnancy and the Puerperium. Neurol Clin 37:31–51. https://doi.org/10.1016/j.ncl.2018.09.004CrossRefPubMed

50.

Pareyson D, Pantaleoni C, Eleopra R et al (2021) Neuro-telehealth for fragile patients in a tertiary referral neurological institute during the COVID-19 pandemic in Milan, Lombardy. Neurol Sci 42:2637–2644. https://doi.org/10.1007/s10072-021-05252-9CrossRefPubMedPubMedCentral

51.

Grazzi L, Rizzoli P, Raggi A (2023) How the COVID-19 emergency changed our modality to treat patients with migraine: a positive aspect of the pandemic. Neurol Sci 44:809–810. https://doi.org/10.1007/s10072-022-06585-9CrossRefPubMed

52.

van de Graaf DL, Schoonman GG, Habibović M, Pauws SC (2021) Towards eHealth to support the health journey of headache patients: a scoping review. J Neurol 268:3646–3665. https://doi.org/10.1007/s00415-020-09981-3CrossRefPubMed

53.

Noutsios CD, Boisvert-Plante V, Perez J, Hudon J, Ingelmo P (2021) Telemedicine applications for the evaluation of patients with Non-acute Headache: a narrative review. J Pain Res 14:1533–1542. https://doi.org/10.2147/JPR.S309542CrossRefPubMedPubMedCentral

54.

Bentivegna E, Tassorelli C, De Icco R, Sances G, Martelletti P (2022) Tele-healthcare in migraine medicine: from diagnosis to monitoring treatment outcomes. Expert Rev Neurother 22:237–243. https://doi.org/10.1080/14737175.2022.2045954CrossRefPubMed

55.

Spina E, Tedeschi G, Russo A et al (2022) Telemedicine application to headache: a critical review. Neurol Sci 43:3795–3801. https://doi.org/10.1007/s10072-022-05910-6CrossRefPubMedPubMedCentral

56.

Lipton RB, Sico J, Seng EK (2023) Migraine screening in English and Spanish. Headache 63(7):843–845. https://doi.org/10.1111/head.14520CrossRefPubMed

57.

Lipton RB, Dodick D, Sadovsky R et al (2003) A self-administered screener for migraine in primary care: the ID Migraine validation study. Neurology 61(3):375–382. https://doi.org/10.1212/01.wnl.0000078940.53438.83CrossRefPubMed

58.

Bigio J, MacLean E, Vasquez NA et al (2022) Most common reasons for primary care visits in low- and middle-income countries: a systematic review. PLOS Glob Public Health 2(5):e0000196. https://doi.org/10.1371/journal.pgph.0000196CrossRefPubMedPubMedCentral

59.

Finley CR, Chan DS, Garrison S et al (2018) What are the most common conditions in primary care? Systematic review. Can Fam Physician 64(11):832–840PubMedPubMedCentral

60.

Evlice A, Genç H, Uluduz D et al (2023) Secondary headache disorders in Turkey, the Middle East, Asia, and Africa: a cross-sectional, multicenter study. Cephalalgia 43(8):3331024231194024. https://doi.org/10.1177/03331024231194024CrossRefPubMed

61.

Headache Classification Committee of the International Headache Society (IHS) (2018) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 38:1-211. https://doi.org/10.1177/0333102417738202

62.

Burch R (2019) Migraine and tension-type headache: diagnosis and treatment. Med Clin North Am 103:215–233. https://doi.org/10.1016/j.mcna.2018.10.003CrossRefPubMed

63.

Eigenbrodt AK, Ashina H, Khan S et al (2021) Diagnosis and management of migraine in ten steps. Nat Rev Neurol 17:501–514. https://doi.org/10.1038/s41582-021-00509-5CrossRefPubMedPubMedCentral

64.

Suri H, Ailani J (2021) Cluster headache: a review and update in treatment. Curr Neurol Neurosci Rep 21:31. https://doi.org/10.1007/s11910-021-01114-1CrossRefPubMed

65.

Evers S, Summ O (2021) Neurostimulation Treatment in Chronic Cluster Headache-a narrative review. Curr Pain Headache Rep 25:81. https://doi.org/10.1007/s11916-021-00989-6CrossRefPubMedPubMedCentral

66.

Franzini A, Clerici E, Navarria P, Picozzi P (2022) Gamma Knife radiosurgery for the treatment of cluster headache: a systematic review. Neurosurg Rev 45:1923–1931. https://doi.org/10.1007/s10143-021-01725-9CrossRefPubMed

67.

Robbins MS, Robertson CE, Ailani J, Levin M, Friedman DI, Dodick DW (2016) Procedural Headache Medicine in Neurology Residency Training: a Survey of US Program directors. Headache 56:79–85. https://doi.org/10.1111/head.12695CrossRefPubMed

68.

Minen M, Shome A, Halpern A et al (2016) A migraine management training program for primary care providers: an overview of a survey and pilot study findings, lessons learned, and considerations for further research. Headache 56:725–740. https://doi.org/10.1111/head.12803CrossRefPubMedPubMedCentral

69.

Ahmed ZA, Faulkner LR (2016) Headache Education in Adult Neurology Residency: a Survey of Program directors and Chief residents. Headache 56:871–877. https://doi.org/10.1111/head.12822CrossRefPubMed

70.

Ong JJY, Chan YC (2017) Medical undergraduate survey on Headache Education in Singapore: knowledge, perceptions, and Assessment of Unmet needs. Headache 57:967–978. https://doi.org/10.1111/head.13110CrossRefPubMed

71.

Raieli V, Loiacono C, Messina LM, Correnti E, Brighina F (2018) Is a digital platform useful in headache training? A 4-year Italian experience. Neurol Sci 39:2223–2224. https://doi.org/10.1007/s10072-018-3540-xCrossRefPubMed

72.

Pace A, Orr SL, Rosen NL, Safdieh JE, Cruz GB, Sprouse-Blum AS (2021) The current state of headache medicine education in the United States and Canada: an observational, survey-based study of neurology clerkship directors and curriculum deans. Headache 61:854–862. https://doi.org/10.1111/head.14134CrossRefPubMed

73.

Do TP, Dømgaard M, Stefansen S, Kristoffersen ES, Ashina M, Hansen JM (2022) Barriers and gaps in headache education: a national cross-sectional survey of neurology residents in Denmark. BMC Med Educ 22:233. https://doi.org/10.1186/s12909-022-03299-6CrossRefPubMedPubMedCentral

74.

Marzouk M, Seng EK (2021) The impact of parental migraine on children. Curr Pain Headache Rep 24:81. https://doi.org/10.1007/s11916-020-00915-2CrossRefPubMed

75.

Lipton RB, Buse DC, Adams AM, Varon SF, Fanning KM, Reed ML (2017) Family Impact of Migraine: development of the impact of Migraine on partners and adolescent children (IMPAC) scale. Headache 57:570–585. https://doi.org/10.1111/head.13028CrossRefPubMedPubMedCentral

76.

Buse DC, Scher AI, Dodick DW et al (2016) Impact of Migraine on the Family: Perspectives of People With Migraine and Their Spouse/Domestic Partner in the CaMEO Study. Mayo Clin Proc 91:596–611. https://doi.org/10.1016/j.mayocp.2016.02.013CrossRef

77.

Arruda MA, Bigal ME (2012) Migraine and behavior in children: influence of maternal headache frequency. J Headache Pain 13:395–400. https://doi.org/10.1007/s10194-012-0441-xCrossRefPubMedPubMedCentral

78.

Pohl H, Gantenbein AR, Sandor PS, Schoenen J, Andrée C (2020) Interictal burden of Cluster Headache: results of the EUROLIGHT Cluster Headache Project, an Internet-Based, cross-sectional study of people with cluster headache. Headache 60:360–369. https://doi.org/10.1111/head.13711CrossRefPubMed

79.

Buse DC, Fanning KM, Reed ML et al (2019) Life with Migraine: effects on relationships, Career, and Finances from the chronic migraine epidemiology and outcomes (CaMEO) study. Headache 59:1286–1299. https://doi.org/10.1111/head.13613CrossRefPubMedPubMedCentral

80.

Buse DC, Powers SW, Gelfand AA et al (2018) Adolescent perspectives on the Burden of a parent’s migraine: results from the CaMEO study. Headache 58:512–524. https://doi.org/10.1111/head.13254CrossRefPubMed

81.

Seng EK, Mauser ED, Marzouk M, Patel ZS, Rosen N, Buse DC (2019) When Mom has Migraine: an observational study of the impact of parental migraine on adolescent children. Headache 59:224–234. https://doi.org/10.1111/head.13433CrossRefPubMed

82.

Natalucci G, Faedda N, Baglioni V, Guidetti V (2020) The relationship between parental Care and Pain in Children with Headache: a narrative review. Headache 60:1217–1224. https://doi.org/10.1111/head.13822CrossRefPubMed

83.

May A, Schulte LH (2016) Chronic migraine: risk factors, mechanisms and treatment. Nat Rev Neurol 12:455–464. https://doi.org/10.1038/nrneurol.2016.93CrossRefPubMed

84.

Diener HC, Holle D, Solbach K, Gaul C (2016) Medication-overuse headache: risk factors, pathophysiology and management. Nat Rev Neurol 12:575–583. https://doi.org/10.1038/nrneurol.2016.124CrossRefPubMed

85.

Cho SJ, Chu MK (2015) Risk factors of chronic daily headache or chronic migraine. Curr Pain Headache Rep 19:465. https://doi.org/10.1007/s11916-014-0465-9CrossRefPubMed

86.

Schramm S, Tenhagen I, Schmidt B et al (2021) Prevalence and risk factors of migraine and non-migraine headache in older people - results of the Heinz Nixdorf Recall study. Cephalalgia 41:649–664. https://doi.org/10.1177/0333102420977183CrossRefPubMed

87.

Fagernæs CF, Heuch I, Zwart JA, Winsvold BS, Linde M, Hagen K (2015) Blood pressure as a risk factor for headache and migraine: a prospective population-based study. Eur J Neurol 22(156–62):e10-11. https://doi.org/10.1111/ene.12547CrossRef

88.

Elbadawi ASA, Albalawi AFA, Alghannami AK et al (2021) Cluster headache and Associated Risk factors: a systemic review and Meta-analysis. Cureus 13:e19294. https://doi.org/10.7759/cureus.19294CrossRefPubMedPubMedCentral

89.

Xie W, Li R, He M et al (2020) Prevalence and risk factors associated with headache amongst medical staff in South China. J Headache Pain 21:5. https://doi.org/10.1186/s10194-020-1075-zCrossRefPubMedPubMedCentral

90.

D’Amico D, Sansone E, Grazzi L et al (2018) Multimorbidity in patients with chronic migraine and medication overuse headache. Acta Neurol Scand 138:515–522. https://doi.org/10.1111/ane.13014CrossRefPubMed

91.

Kuo FH, Lee CY, Li JP et al (2020) Migraine as a risk factor for peripheral artery occlusive Disease: a Population-based Cohort Study. Int J Environ Res Public Health 17:8549. https://doi.org/10.3390/ijerph17228549CrossRefPubMedPubMedCentral

92.

Gelfand AA, Fullerton HJ, Jacobson A et al (2015) Is migraine a risk factor for pediatric Stroke? Cephalalgia 35:1252–1260. https://doi.org/10.1177/0333102415576222CrossRefPubMedPubMedCentral

93.

Hassan M, Belavadi R, Gudigopuram SVR et al (2021) Migraine and Stroke: in search of Shared pathways, mechanisms, and risk factors. Cureus 13:e20202. https://doi.org/10.7759/cureus.20202CrossRefPubMedPubMedCentral

94.

Norton J, Portet F, Gabelle A et al (2016) Are migraine and non-migrainous headache risk factors for Stroke in the elderly? Findings from a 12-year cohort follow-up. Eur J Neurol 23:1463–1470. https://doi.org/10.1111/ene.13060CrossRefPubMedPubMedCentral

95.

Tekgol Uzuner G, Yalın OO, Uluduz D, Ozge A, Uzuner N (2021) Migraine and cardiovascular risk factors: a clinic-based study. Clin Neurol Neurosurg 200:106375. https://doi.org/10.1016/j.clineuro.2020.106375CrossRefPubMed

96.

Elgendy IY, Nadeau SE, Bairey Merz CN et al (2019) Migraine Headache: an under-appreciated risk factor for Cardiovascular Disease in Women. J Am Heart Assoc 8:e014546. https://doi.org/10.1161/JAHA.119.014546CrossRefPubMedPubMedCentral

97.

Kurth T, Rist PM, Ridker PM, Kotler G, Bubes V, Buring JE (2020) Association of Migraine with Aura and other risk factors with Incident Cardiovascular Disease in Women. JAMA 323:2281–2289. https://doi.org/10.1001/jama.2020.7172CrossRefPubMedPubMedCentral

98.

Klein A, Schankin CJ (2021) Visual snow syndrome, the spectrum of perceptual disorders, and migraine as a common risk factor: a narrative review. Headache 61:1306–1313. https://doi.org/10.1111/head.14213CrossRefPubMedPubMedCentral

99.

Welander NZ, Mwinyi J, Asif S, Schiöth HB, Skalkidou A, Fransson E (2021) Migraine as a risk factor for mixed symptoms of peripartum depression and anxiety in late pregnancy: a prospective cohort study. J Affect Disord 295:733–739. https://doi.org/10.1016/j.jad.2021.08.119CrossRefPubMed

100.

Guido D, Leonardi M, Mellor-Marsá B et al (2020) Pain rates in general population for the period 1991–2015 and 10-years prediction: results from a multi-continent age-period-cohort analysis. J Headache Pain 21:52. https://doi.org/10.1186/s10194-020-01108-3CrossRefPubMedPubMedCentral

101.

Raggi A, Leonardi M, Mellor-Marsá B et al (2020) Predictors of pain in general ageing populations: results from a multi-country analysis based on ATHLOS harmonized database. J Headache Pain 21:45. https://doi.org/10.1186/s10194-020-01116-3CrossRefPubMedPubMedCentral

102.

Sanchez-Niubo A, Forero CG, Wu YT et al (2021) Development of a common scale for measuring healthy ageing across the world: results from the ATHLOS consortium. Int J Epidemiol 50:880–892. https://doi.org/10.1093/ije/dyaa236CrossRefPubMed

103.

Grazzi L, D’Amico D, Guastafierro E et al (2023) Efficacy of mindfulness added to treatment as usual in patients with chronic migraine and medication overuse headache: a phase-III single-blind randomized-controlled trial (the MIND-CM study). J Headache Pain 24:86. https://doi.org/10.1186/s10194-023-01630-0CrossRefPubMedPubMedCentral

104.

D’Amico D, Grazzi L, Guastafierro E, Sansone E, Leonardi M, Raggi A (2021) Withdrawal failure in patients with chronic migraine and medication overuse headache. Acta Neurol Scand 144:408–417. https://doi.org/10.1111/ane.13475CrossRefPubMedPubMedCentral

105.

GBD 2016 Meningitis Collaborators (2018) Global, regional, and national burden of Meningitis, 1990–2016: a systematic analysis for the global burden of Disease Study 2016. Lancet Neurol 17:1061–1082. https://doi.org/10.1016/S1474-4422(18)30387-9CrossRef

106.

GBD 2016 Neurology Collaborators (2019) Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the global burden of Disease Study 2016. Lancet Neurol 18:459–480. https://doi.org/10.1016/S1474-4422(18)30499-XCrossRef

107.

Raggi A, Leonardi M (2020) Burden of brain disorders in Europe in 2017 and comparison with other non-communicable Disease groups. J Neurol Neurosurg Psychiatry 91:104–105. https://doi.org/10.1136/jnnp-2019-320466CrossRefPubMed

108.

Raggi A, Monasta L, Beghi E et al (2022) Incidence, prevalence and disability associated with neurological disorders in Italy between 1990 and 2019: an analysis based on the global burden of Disease Study 2019. J Neurol 269:2080–2098. https://doi.org/10.1007/s00415-021-10774-5CrossRefPubMed

109.

Fernández-de-Las-Peñas C, Navarro-Santana M, Gómez-Mayordomo V et al (2021) Headache as an acute and post-COVID-19 symptom in COVID-19 survivors: a meta-analysis of the current literature. Eur J Neurol 28:3820–3825. https://doi.org/10.1111/ene.15040CrossRefPubMedPubMedCentral

110.

Castaldo M, Waliszewska-Prosół M, Koutsokera M et al (2022) Headache onset after vaccination against SARS-CoV-2: a systematic literature review and meta-analysis. J Headache Pain 23:41. https://doi.org/10.1186/s10194-022-01400-4CrossRefPubMedPubMedCentral

111.

Tana C, Giamberardino MA, Martelletti P (2023) Long COVID and especially headache syndromes. Curr Opin Neurol 36(3):168–174. https://doi.org/10.1097/WCO.0000000000001153CrossRefPubMed

112.

Martelletti P, Bentivegna E, Spuntarelli V, Luciani M (2021) Long-COVID headache. SN Compr Clin Med 3:1704–1706. https://doi.org/10.1007/s42399-021-00964-7CrossRefPubMedPubMedCentral

113.

Voormolen DC, Haagsma JA, Polinder S et al (2019) Post-concussion symptoms in complicated vs. Uncomplicated Mild Traumatic Brain Injury Patients at Three and Six Months Post-Injury: Results from the CENTER-TBI Study. J Clin Med Res 8:1921. https://doi.org/10.3390/jcm8111921CrossRef

114.

Aaseth K, Grande RB, Kvárner KJ, Gulbrandsen P, Lundqvist C, Russell MB (2008) Prevalence of secondary chronic headaches in a Population-based sample of 30-44-year-old persons. The Akershus Study of Chronic Headache. Cephalalgia 28:705–713. https://doi.org/10.1111/j.1468-2982.2008.01577.xCrossRefPubMed

115.

Rasmussen BK, Olesen J (1992) Symptomatic and nonsymptomatic headaches in a general population. Neurology 42:1225–1231. https://doi.org/10.1212/wnl.42.6.1225CrossRefPubMed

116.

Benemei S, Labastida-Ramírez A, Abramova E et al (2020) Persistent post-traumatic headache: a migrainous loop or not? The preclinical evidence. J Headache Pain 21:90. https://doi.org/10.1186/s10194-020-01135-0CrossRefPubMedPubMedCentral

117.

Taylor FR (2015) Tobacco, Nicotine, and Headache. Headache 55:1028–1044. https://doi.org/10.1111/head.12620CrossRefPubMed

118.

Rozen TD (2018) Cluster headache clinical phenotypes: Tobacco Nonexposed (never smoker and no parental secondary smoke exposure as a child) versus Tobacco-Exposed: results from the United States Cluster Headache Survey. Headache 58:688–699. https://doi.org/10.1111/head.13295CrossRefPubMed

119.

Friedman DI, De ver Dye T (2009) Migraine and the environment. Headache. 49:941 – 52. https://doi.org/10.1111/j.1526-4610.2009.01443.x

120.

Martinelli D, Pocora MM, De Icco R, Putortì A, Tassorelli C (2022) Triggers of migraine: where do we stand? Curr Opin Neurol 35:360–366. https://doi.org/10.1097/WCO.0000000000001065CrossRefPubMed

121.

Shimizu T, Sakai F, Miyake H et al (2021) Disability, quality of life, productivity impairment and employer costs of migraine in the workplace. J Headache Pain 22:29. https://doi.org/10.1186/s10194-021-01243-5CrossRefPubMedPubMedCentral

122.

Raggi A, Leonardi M, Sansone E, Curone M, Grazzi L, D’Amico D (2020) The cost and the value of treatment of medication overuse headache in Italy: a longitudinal study based on patient-derived data. Eur J Neurol 27:62–e1. https://doi.org/10.1111/ene.14034

123.

de Begasse O, Sakai F (2022) Migraine in the workplace. eNeurologicalSci 27:100408. https://doi.org/10.1016/j.ensci.2022.100408CrossRef

124.

Tietjen GE, Karmakar M, Amialchuk AA (2017) Emotional abuse history and migraine among young adults: a retrospective cross-sectional analysis of the add Health dataset. Headache 57:45–59. https://doi.org/10.1111/head.12994CrossRefPubMed

125.

Tietjen GE, Brandes JL, Peterlin BL et al (2010) Childhood maltreatment and migraine (part II). Emotional abuse as a risk factor for headache chronification. Headache 50:32–41. https://doi.org/10.1111/j.1526-4610.2009.01557.xCrossRefPubMed

126.

Tietjen GE, Buse DC, Fanning KM, Serrano D, Reed ML, Lipton RB (2015) Recalled maltreatment, migraine, and tension-type headache: results of the AMPP study. Neurology 84:132–140. https://doi.org/10.1212/WNL.0000000000001120CrossRefPubMedPubMedCentral

127.

Juang KD, Wang SJ, Fuh JL, Lu SR, Chen YS (2004) Association between adolescent chronic daily headache and childhood adversity: a community-based study. Cephalalgia 24(1):54–59. https://doi.org/10.1111/j.1468-2982.2004.00643.xCrossRefPubMed

128.

Işik U, Topuzoğlu A, Ay P et al (2009) The prevalence of headache and its association with socioeconomic status among schoolchildren in Istanbul. Turk Headache 49:697–703. https://doi.org/10.1111/j.1526-4610.2009.01339.xCrossRef

129.

Bigal ME, Lipton RB, Winner P et al (2007) Migraine in adolescents: association with socioeconomic status and family history. Neurology 69:16–25. https://doi.org/10.1212/01.wnl.0000265212.90735.64CrossRefPubMed

130.

Atasoy HT, Unal AE, Atasoy N, Emre U, Sumer M (2005) Low income and education levels may cause medication overuse and chronicity in migraine patients. Headache 45:25–31. https://doi.org/10.1111/j.1526-4610.2005.05006.xCrossRefPubMed

131.

Guidetti V, Dosi C, Bruni O (2014) The relationship between sleep and headache in children: implications for treatment. Cephalalgia 34:767–776. https://doi.org/10.1177/0333102414541817CrossRefPubMed

132.

Dosi C, Figura M, Ferri R, Bruni O (2015) Sleep and headache. Semin Pediatr Neurol. 22:105–112. https://doi.org/10.1016/j.spen.2015.04.005CrossRefPubMed

133.

Kinik ST, Alehan F, Erol I, Kanra AR (2010) Obesity and paediatric migraine. Cephalalgia 30:105–109. https://doi.org/10.1111/j.1468-2982.2009.01907.xCrossRefPubMed

134.

Verrotti A, Di Fonzo A, Penta L, Agostinelli S, Parisi P (2014) Obesity and headache/migraine: the importance of weight reduction through lifestyle modifications. Biomed Res Int 2014:420858. https://doi.org/10.1155/2014/420858CrossRefPubMedPubMedCentral

135.

Lateef TM, Merikangas KR, He J et al (2009) Headache in a national sample of American children: prevalence and comorbidity. J Child Neurol 24:536–543. https://doi.org/10.1177/0883073808327831CrossRefPubMedPubMedCentral

136.

Abu-Arafeh I, Razak S, Sivaraman B, Graham C (2010) Prevalence of headache and migraine in children and adolescents: a systematic review of population-based studies. Dev Med Child Neurol 52:1088–1097. https://doi.org/10.1111/j.1469-8749.2010.03793.xCrossRefPubMed

137.

Ashina M (2019) The most important advances in headache research in 2018. Lancet Neurol 18:5–6. https://doi.org/10.1016/S1474-4422(18)30434-4CrossRefPubMed

138.

Goadsby PJ (2021) Headache research in 2020: disrupting and improving practice. Lancet Neurol 20:7–8. https://doi.org/10.1016/S1474-4422(20)30457-9CrossRefPubMed

139.

Ashina M, Terwindt GM, Al-Karagholi MA et al (2021) Migraine: Disease characterisation, biomarkers, and precision medicine. Lancet 397:1496–1504. https://doi.org/10.1016/S0140-6736(20)32162-0CrossRefPubMed

140.

Ford I, Norrie J (2016) Pragmatic trials. N Engl J Med 375:454–463. https://doi.org/10.1056/NEJMra1510059CrossRefPubMed

141.

Schwedt TJ, Tassorelli C, Silberstein SD et al (2022) Guidelines of the International Headache Society for Clinic-Based Headache Registries. Cephalalgia 42:1099–1115. https://doi.org/10.1177/03331024221099035CrossRefPubMedPubMedCentral

142.

GBD 2019 Universal Health Coverage Collaborators (2020) Measuring universal health coverage based on an index of effective coverage of health services in 204 countries and territories, 1990–2019: a systematic analysis for the global burden of Disease Study 2019. Lancet 396(10258):1250–1284. https://doi.org/10.1016/S0140-6736(20)30750-9CrossRef

143.

Chung PW, Lee MJ, Park JW et al (2019) Differences of Cluster Headache on the basis of sex in the Korean cluster Headache Registry. Headache 59:1722–1730. https://doi.org/10.1111/head.13637CrossRefPubMed

144.

Hornik CP, Gelfand AA, Szperka CL et al (2020) Development of a prospective real-World Data Clinical Registry of children and adolescents with Migraine. Headache 60:405–415. https://doi.org/10.1111/head.13714CrossRefPubMed

145.

Pearl TA, Dumkrieger G, Chong CD, Dodick DW, Schwedt TJ (2020) Sensory hypersensitivity symptoms in Migraine with vs without aura: results from the American Registry for Migraine Research. Headache 60:506–514. https://doi.org/10.1111/head.13745CrossRefPubMed

146.

Sipilä JOT, Ruuskanen JO, Rautava P, Kytö V (2020) Adult Migraine Hospital Admission Trends in Finland: a Nationwide Registry Study. J Clin Med 9:320. https://doi.org/10.3390/jcm9020320CrossRefPubMedPubMedCentral

147.

Pearl TA, Dumkrieger G, Chong CD, Dodick DW, Schwedt TJ (2020) Impact of depression and anxiety symptoms on patient-reported outcomes in patients with migraine: results from the American Registry for Migraine Research (ARMR). Headache 60:1910–1919. https://doi.org/10.1111/head.13911CrossRefPubMed

148.

Ishii R, Schwedt TJ, Kim SK, Dumkrieger G, Chong CD, Dodick DW (2020) Effect of Migraine on Pregnancy Planning: Insights From the American Registry for Migraine Research. Mayo Clin Proc 95:2079–2089. https://doi.org/10.1016/j.mayocp.2020.06.053CrossRefPubMed

149.

Delussi M, Gentile E, Coppola G et al (2020) Investigating the effects of COVID-19 Quarantine in Migraine: an observational cross-sectional study from the Italian National Headache Registry (RICe). Front Neurol 11:597881. https://doi.org/10.3389/fneur.2020.597881CrossRefPubMedPubMedCentral

150.

Trivedi M, Dumkrieger G, Chong CD, Dodick DW, Schwedt TJ (2021) Impact of abuse on migraine-related sensory hypersensitivity symptoms: results from the American Registry for Migraine Research. Headache 61:740–754. https://doi.org/10.1111/head.14100CrossRefPubMed

151.

Chung PW, Kim BS, Park JW et al (2021) Smoking history and clinical features of Cluster Headache: results from the Korean cluster Headache Registry. J Clin Neurol 17:229–235. https://doi.org/10.3988/jcn.2021.17.2.229CrossRefPubMedPubMedCentral

152.

Belvís R, Irimia P, Pozo-Rosich P et al (2021) MAB-MIG: registry of the Spanish neurological society of erenumab for migraine prevention. J Headache Pain 22:74. https://doi.org/10.1186/s10194-021-01267-xCrossRefPubMedPubMedCentral

153.

Park HK, Chu MK, Oh SY et al (2022) Interim analysis of the Registry for load and management of medication overuse headache (RELEASE): a multicenter, comprehensive medication overuse headache registry. Cephalalgia 42:455–465. https://doi.org/10.1177/03331024211057184CrossRefPubMed

154.

Leibovit-Reiben Z, Ishii R, Dodick DW et al (2022) The impact of pre-morbid headaches on headache features and long-term health outcomes following traumatic brain injury: insights from the American Registry for Migraine Research. Headache 62:566–576. https://doi.org/10.1111/head.14311CrossRefPubMed

155.

Ruscheweyh R, Klonowski T, Goßrau G (2022) The headache registry of the German migraine and Headache Society (DMKG): baseline data of the first 1,351 patients. J Headache Pain 23:74. https://doi.org/10.1186/s10194-022-01447-3CrossRefPubMedPubMedCentral

156.

Barbanti P, Egeo G, Aurilia C et al (2022) The first report of the Italian Migraine Registry (I-GRAINE). Neurol Sci 43(9):5725–5728. https://doi.org/10.1007/s10072-022-06214-5CrossRefPubMed

157.

World Health Organization (2022) Optimizing brain health across the life course: WHO position paper. World Health Organization, Geneva

158.

Owolabi MO, Leonardi M, Bassetti C et al (2022) The neurology revolution. Lancet Neurol 21:960–961. https://doi.org/10.1016/S1474-4422(22)00394-5CrossRefPubMed

159.

The Lancet Neurology (2022) WHO launches its global action plan for brain health. Lancet Neurol 21:671. https://doi.org/10.1016/S1474-4422(22)00266-6CrossRefPubMed

Title: The World Health Organization Intersectoral Global Action Plan on Epilepsy and Other Neurological Disorders and the headache revolution: from headache burden to a global action plan for headache disorders
Authors: Matilde Leonardi
Paolo Martelletti
Rami Burstein
Arianna Fornari
Licia Grazzi
Alla Guekht
Richard B. Lipton
Dimos Dimitrios Mitsikostas
Jes Olesen
Mayowa Ojo Owolabi
Elena Ruiz De la Torre
Simona Sacco
Timothy J. Steiner
Nirmal Surya
Takao Takeshima
Cristina Tassorelli
Shuu-Jiun Wang
Tissa Wijeratne
Shengyuan Yu
Alberto Raggi
Publication date: 01-12-2024
Publisher: Springer Milan
Keywords: Headache
Migraine
Epilepsy
Tension Headache
Published in: The Journal of Headache and Pain / Issue 1/2024
Print ISSN: 1129-2369
Electronic ISSN: 1129-2377
DOI: https://doi.org/10.1186/s10194-023-01700-3

At a glance: The STEP trials

Springer Medicine

The World Health Organization Intersectoral Global Action Plan on Epilepsy and Other Neurological Disorders and the headache revolution: from headache burden to a global action plan for headache disorders

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2024

The burden of headache disorders in the adult general population of the Kingdom of Saudi Arabia: estimates from a cross-sectional population-based study including a health-care needs assessment

How do metabolic diseases affect migraine?

Female-selective mechanisms promoting migraine

Lipopolysaccharide, VE-cadherin, HMGB1, and HIF-1α levels are elevated in the systemic circulation in chronic migraine patients with medication overuse headache: evidence of leaky gut and inflammation

CGRP-targeted medication in chronic migraine - systematic review

The prevalence of headache in the adult population of Morocco: a cross-sectional population-based study